DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183934

Active surveillance of adverse drug reactions in patients with rheumatoid arthritis in a tertiary care teaching hospital

Nalini R., Keerthi D., Meenakshi B., Ezhil Ramya J., Vidhya .

Abstract


Background: Drugs used in the treatment of rheumatoid arthritis show significant toxicity and morbidity. The objective of the study was to evaluate the nature and incidence of adverse drug reaction in patients with rheumatoid arthritis on anti-rheumatic drugs and to assess the causality and severity of the documented adverse drug reactions.

Methods: The prospective observational study was done for two months in rheumatology outpatient department. All patients were interviewed for basic details, treatment history and adverse drug reactions and were recorded. Causality assessment and severity assessment of the recorded adverse drug reactions were done.

Results: About 283 patients attended the rheumatology out-patient department during the two months period out of which 57 patients had one or more adverse drug reaction. The incidence of adverse drug reaction observed in rheumatology out-patient department to anti rheumatic drug was 20.14%. A total of 145 adverse drug reactions were noted in 57 patients. The most common adverse drug reaction reported was epigastric pain (6.89%) followed by headache and dyslipidemia (6.25%). The most common system associated with adverse drug reaction was gastrointestinal system (29.66%) followed by central nervous system and cardiovascular system (15.86%). Reported adverse drug reactions were assessed for causality and maximum belonged to probable (66.9%). Severity assessment revealed that most of the adverse drug reactions were mild (74.48%) in nature.

Conclusions: Active surveillance for adverse drug reactions to anti rheumatic drug in patients with rheumatoid arthritis will allow early detection of adverse drug reactions and timely intervention to provide maximum benefit to the patients.


Keywords


Adverse drug reaction, Corticosteroids, Disease modifying anti-rheumatic drugs, Rheumatoid arthritis

Full Text:

PDF

References


Shah A, E. William St Clair. Rheumatoid arthritis. Harrison's principles of internal medicine. 19th Ed. Newyork, Mc Graw Hill. 2015:2136-49.

Buhroo AM, Baba AN. Adverse effects of low-dose methotrexate in patients with rheumatoid arthritis. IJPMR. 2006;17(2):21-5.

Waserman A. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84(11):1245-52.

Singh P, Bharat S, Bano M, Gaur S, Srivastava B. Adverse drug reaction in rheumatoid arthritis patients taking combination DMARDs. J Med Sci Clin Res. 2016;4(8):12115-24.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.

Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26.

Ahmed A. Negum, Daniel E Furst. Non-steroidal antiinflammatory drugs, disease modifying antirheumatic drugs, non-opioid analgesics and drugs used in gout. Bertram G Katzung Katzung Basic and clinical pharmacology,14th Ed. New York, Mc Graw Hill. 2018:649-659.

Ankoor Shah, E.William St. Clair. Rheumatoid arthritis. Anthony S. Fauci Harrisons Rheumatology. 3rd Ed. Newyork, McGrawHill. 2013:87-105.

Bernard P. Schimmer and John W. Funder. Adrenocorticotropic hormone, Adrenal steroids and the Adrenal cortex. Goodman and Gillman’s Pharmacological Basis of Therapeutics. 13th Ed. Newyork, NY: Mc Graw Hill. 2018:845-61.

Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the Br Assoc Dermatol. Rheumatol. 2006 Aug 28;47(6):924-5.

The use of the WHO-UMC system for standardized case causality assessment. Available at: http:// whoumc.org/Graphics/24734.pdf. Accessed on 12 June 2018.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Sys Pharma. 1992 Sep 1;49(9):2229-32.

Machado-Alba JE, Ruiz AF, Machado-Duque ME. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Rev Panam Salud Publica. 2014;36(6):396-401.

Alastair Innes J. Rheumatology and bone disease. Davidson’s Essentials of Medicine. Elsevier. 2nd ed. 2016:561-604.

Haraoui B, Jovaisas A, Bensen WG, et al. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD 2015. Available at: http://dx.doi.org/10.1136/rmdopen. Accessed on 2 July 2018.

Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS. Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharmaceut J. 2012;20(4):301-5.

van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Medicine. 2009 Dec;7(1):12.

Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheumatic Dis. 2006 Mar 1;65(3):285-93.